(Q46131224)

19 December 2017

title

Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma (English)

1 reference

19 December 2017

1 reference

1 reference

Marc C Chamberlain

1

1 reference

19 December 2017

Sandra Johnston

series ordinal

2

1 reference

19 December 2017

language of work or name

English

0 references

publication date

1 April 2009

1 reference

19 December 2017

published in

Cancer

1 reference

19 December 2017

volume

115

1 reference

19 December 2017

issue

8

1 reference

19 December 2017

page(s)

1734-1743

1 reference

19 December 2017

Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

Epidemiology of venous thromboembolism in 9489 patients with malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

External irradiation followed by an interstitial high activity iodine-125 implant “boost” in the initial treatment of malignant gliomas: NCOG study 6G-82-2 gliomas: NCOG study 6H-82-2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

The future of therapy for glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Radiosurgery as part of the initial management of patients with malignant gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Intravenous carboplatin for recurrent malignant glioma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Carboplatin and recurrent childhood brain tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

A comparison of two simple hazard ratio estimators based on the logrank test

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Irinotecan therapy in adults with recurrent or progressive malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Venous thromboembolism and survival in patients with high-grade glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24179

7 January 2021

Identifiers

DOI

10.1002/CNCR.24179

1 reference

19 December 2017

1 reference

19 December 2017